| | Identification | Back Directory |  | [Name] 
 BERBERINE ACID SULFATE
 |  | [CAS] 
 633-66-9
 |  | [Synonyms] 
 Nsc150444
 berberinebisulfate
 siarczanuberberyny
 acidberberinesulfate
 berberinesulfate(1:1)
 BERBERINE SULFATE(RG)
 HydroberbeaiMe Sulfate
 BERBERINE ACID SULFATE
 BERBERINE ACID SULPHATE
 Berbamine sulphate acid
 berberinehydrogensulfate
 berberine hydrogen sulphate
 BERBERINE SALTS/TENNATE
/HCL/B-SULPHATE/SULPHATE
 Benzo[G]-1,3-benzodioxolo[5,6-A]quinolizinium, 5,6-dihydro-9,10-dimethoxy-, sulfate
 Berbinium, 7,8,13,13A-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)-, sulfate (1:1)
 Benzo[G]-1,3-benzodioxolo[5,6-A]quinolizinium, 5,6-dihydro-9,10-dimethoxy-, sulfate (1:1)
 |  | [EINECS(EC#)] 
 211-196-4
 |  | [Molecular Formula] 
 C20H19NO8S
 |  | [MDL Number] 
 MFCD00075789
 |  | [MOL File] 
 633-66-9.mol
 |  | [Molecular Weight] 
 433.43
 | 
 | Questions And Answer | Back Directory |  | [Uses] 
 Berberine Sulfate is an isoquinoline alkaloid with chemopreventative properties. It is used in the preparation of derivatives showing activity against leishmaniasis and malaria.
 | 
 | Chemical Properties | Back Directory |  | [Melting point ] 
 274-275 °C (decomp)
 |  | [storage temp. ] 
 Inert atmosphere,Room Temperature
 |  | [solubility ] 
 Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
 |  | [form ] 
 Powder
 |  | [color ] 
 White to yellow
 |  | [Stability:] 
 Hygroscopic
 | 
 | Hazard Information | Back Directory |  | [Chemical Properties] 
 Yellow needle-shaped crystals. Odorless, extremely bitter. MP 274°C. Soluble in water (1:30) and ethanol.
 |  | [in vivo] 
 
 Berberine sulfate (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice[1]. | Animal Model: | 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts[1] |  | Dosage: | 10, 30, or 50 mg/kg/day |  | Administration: | Gastrointestinal gavage; for 10 consecutive days |  | Result: | Showed inhibitory rates of 33.1% and 45.3% at doses of 30 and 50 mg/kg/day. | 
 |  | [storage] 
 -20°C, sealed storage, away from moisture
 | 
 |  |